vorinostat has been researched along with Clear Cell Sarcoma of Soft Tissue in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mae, H | 1 |
| Outani, H | 1 |
| Imura, Y | 1 |
| Chijimatsu, R | 1 |
| Inoue, A | 1 |
| Kotani, Y | 1 |
| Yasuda, N | 1 |
| Nakai, S | 1 |
| Nakai, T | 1 |
| Takenaka, S | 1 |
| Okada, S | 1 |
1 other study available for vorinostat and Clear Cell Sarcoma of Soft Tissue
| Article | Year |
|---|---|
Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene
Topics: Cell Cycle Proteins; Histone Deacetylase Inhibitors; Humans; Nuclear Proteins; RNA-Binding Protein E | 2023 |